share_log

Arvinas (NASDAQ:ARVN) Shares Gap Up to $45.55

Arvinas (NASDAQ:ARVN) Shares Gap Up to $45.55

阿维纳斯(纳斯达克:ARVN)股价差距高达45.55美元
Defense World ·  2022/10/01 05:42

Arvinas, Inc. (NASDAQ:ARVN – Get Rating) gapped up before the market opened on Thursday . The stock had previously closed at $45.55, but opened at $46.69. Arvinas shares last traded at $44.50, with a volume of 16 shares.

阿维纳斯,公司(纳斯达克:ARVN-GET评级)在周四开盘前出现缺口。该股此前收盘报45.55美元,开盘报46.69美元。Arvinas的股票最新报44.50美元,成交量为16股。

Analyst Ratings Changes

分析师评级发生变化

A number of equities research analysts have recently commented on ARVN shares. Oppenheimer lowered their price target on shares of Arvinas from $108.00 to $102.00 and set an "outperform" rating for the company in a report on Monday, August 8th. SVB Leerink lowered their price target on shares of Arvinas from $91.00 to $89.00 and set an "outperform" rating for the company in a report on Friday, August 5th. HC Wainwright lowered their price target on shares of Arvinas from $135.00 to $90.00 and set a "buy" rating for the company in a report on Friday, August 5th. Jefferies Financial Group assumed coverage on shares of Arvinas in a report on Tuesday, June 21st. They set a "hold" rating and a $42.00 price target for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Arvinas in a report on Wednesday, September 21st. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $82.13.

一些股票研究分析师最近对ARVN的股票发表了评论。奥本海默将阿维纳斯股票的目标价从108.00美元下调至102.00美元,并在8月8日周一的一份报告中为该公司设定了“跑赢大盘”的评级。SVB Leerink在8月5日周五的一份报告中将Arvinas的股票目标价从91.00美元下调至89.00美元,并为该公司设定了“跑赢大盘”的评级。在周五的一份报告中,HC Wainwright将Arvinas的股票目标价从135.00美元下调至90美元,并将该公司的评级定为“买入”。杰富瑞金融集团在6月21日星期二的一份报告中对Arvinas的股票进行了报道。他们为该公司设定了“持有”评级和42.00美元的目标价。最后,坎托·菲茨杰拉德在9月21日星期三的一份报告中重申了对阿维纳斯股票的“增持”评级。3名研究分析师对该股的评级为持有,13名分析师对该股的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为“中等买入”,平均目标价为82.13美元。

Get
到达
Arvinas
阿维纳斯
alerts:
警报:

Arvinas Price Performance

阿维纳斯性价比

The business's 50-day moving average price is $48.05 and its 200 day moving average price is $50.92. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of -9.98 and a beta of 2.06.

该业务的50日移动均线价格为48.05美元,200日移动均线价格为50.92美元。该公司的市值为23.7亿美元,市盈率为-9.98倍,贝塔系数为2.06。

Arvinas (NASDAQ:ARVN – Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.30). Arvinas had a negative return on equity of 31.16% and a negative net margin of 255.97%. The firm had revenue of $31.30 million for the quarter, compared to analyst estimates of $23.71 million. During the same period in the previous year, the firm posted ($1.03) earnings per share. The company's revenue for the quarter was up 469.1% on a year-over-year basis. As a group, sell-side analysts expect that Arvinas, Inc. will post -4.74 earnings per share for the current year.
阿维纳斯(纳斯达克代码:ARVN-GET Rating)最近一次公布财报是在8月4日星期四。该公司公布本季度每股收益(1.32美元),低于分析师普遍预期的(1.02美元)和(0.30美元)。阿维纳斯的净资产回报率为负31.16%,净利润率为负255.97%。该公司本季度营收为3130万美元,而分析师预期为2371万美元。去年同期,该公司公布的每股收益为1.03美元。该公司当季营收同比增长469.1%。卖方分析师预计,作为一个整体,Arvinas,Inc.本年度每股收益将达到4.74美元。

Insider Activity at Arvinas

阿维纳斯的内幕活动

In related news, insider Ronald Peck sold 1,258 shares of the company's stock in a transaction on Friday, August 12th. The shares were sold at an average price of $68.99, for a total value of $86,789.42. Following the sale, the insider now directly owns 8,154 shares of the company's stock, valued at $562,544.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.78% of the stock is currently owned by corporate insiders.

在相关新闻中,内部人士罗纳德·佩克在8月12日星期五的一次交易中出售了1258股该公司股票。这些股票的平均价格为68.99美元,总价值为86,789.42美元。出售后,这位内部人士现在直接持有该公司8,154股股票,价值562,544.46美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可在此超链接。2.78%的股份目前由企业内部人士持有。

Institutional Trading of Arvinas

阿维纳斯的机构交易

Institutional investors have recently added to or reduced their stakes in the stock. SeaCrest Wealth Management LLC acquired a new stake in shares of Arvinas during the second quarter worth $57,000. Lazard Asset Management LLC acquired a new stake in shares of Arvinas during the first quarter worth $57,000. Amundi acquired a new stake in shares of Arvinas during the second quarter worth $62,000. Federated Hermes Inc. raised its holdings in shares of Arvinas by 80,650.0% during the second quarter. Federated Hermes Inc. now owns 1,615 shares of the company's stock worth $68,000 after purchasing an additional 1,613 shares during the period. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Arvinas by 22.7% during the second quarter. Virtus ETF Advisers LLC now owns 2,880 shares of the company's stock worth $121,000 after purchasing an additional 532 shares during the period. 91.20% of the stock is owned by institutional investors and hedge funds.

机构投资者最近增持或减持了该股。Seacrest Wealth Management LLC在第二季度收购了价值5.7万美元的Arvinas新股。Lazard Asset Management LLC在第一季度收购了价值5.7万美元的Arvinas新股。阿蒙迪在第二季度收购了价值6.2万美元的阿维纳斯新股。联合爱马仕公司在第二季度增持了80,650.0%的Arvinas股票。Federated Hermes Inc.在此期间又购买了1,613股,现在持有1,615股该公司股票,价值6.8万美元。最后,Virtus ETF Advisers LLC在第二季度将其持有的Arvinas股票增加了22.7%。Virtus ETF Advisers LLC在此期间又购买了532股,现在拥有2880股该公司股票,价值12.1万美元。91.20%的股票由机构投资者和对冲基金持有。

About Arvinas

关于阿维纳斯

(Get Rating)

(获取评级)

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.

Arvinas,Inc.是一家临床阶段的生物制药公司,致力于发现、开发和商业化降解致病蛋白的疗法。其主要候选产品包括针对雄激素受体(AR)蛋白的转移性去势耐药前列腺癌(MCRPC)治疗处于I期临床试验的靶向嵌合体(PROTAC)蛋白降解剂Bavdecalutide;用于治疗ER阳性/HER2阴性转移性乳腺癌患者的PROTAC蛋白降解剂ARV-471;以及用于治疗男性mCRPC的研究中口服可用PROTAC蛋白降解剂ARV-766。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Arvinas (ARVN)
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • This Is A Memorable Time To Buy Into Micron Technology
  • Declining Profits Challenge the CarMax Value Proposition
  • Thor Industries Hammers Out A Bottom
  • 免费获取StockNews.com关于Arvinas的研究报告(ARVN)
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat:回顾一周9/26-9/30
  • 这是买入美光科技的难忘时刻
  • 利润下降对CarMax价值主张的挑战
  • 雷神工业走出谷底

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.

接受《阿维纳斯日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Arvinas和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发